Literature DB >> 10505921

Towards evidence based emergency medicine: best BETS from the Manchester Royal Infirmary. Oral or topical antibiotics for impetigo.

J McVicar.   

Abstract

Mesh:

Substances:

Year:  1999        PMID: 10505921      PMCID: PMC1347062          DOI: 10.1136/emj.16.5.364

Source DB:  PubMed          Journal:  J Accid Emerg Med        ISSN: 1351-0622


× No keyword cloud information.
  9 in total

1.  Comparison of mupirocin and erythromycin in the treatment of impetigo.

Authors:  J W Britton; J E Fajardo; B Krafte-Jacobs
Journal:  J Pediatr       Date:  1990-11       Impact factor: 4.406

2.  Comparison of oral cephalexin, topical mupirocin and topical bacitracin for treatment of impetigo.

Authors:  J W Bass; D S Chan; K M Creamer; M W Thompson; F J Malone; T M Becker; S N Marks
Journal:  Pediatr Infect Dis J       Date:  1997-07       Impact factor: 2.129

3.  A bacteriologically controlled, randomized study comparing the efficacy of 2% mupirocin ointment (Bactroban) with oral erythromycin in the treatment of patients with impetigo.

Authors:  S McLinn
Journal:  J Am Acad Dermatol       Date:  1990-05       Impact factor: 11.527

4.  Topical mupirocin treatment of impetigo is equal to oral erythromycin therapy.

Authors:  P M Mertz; D A Marshall; W H Eaglstein; Y Piovanetti; J Montalvo
Journal:  Arch Dermatol       Date:  1989-08

5.  Impetigo contagiosa III. Comparative efficacy of oral erythromycin and topical mupirocin.

Authors:  L L Barton; A D Friedman; A M Sharkey; D J Schneller; E M Swierkosz
Journal:  Pediatr Dermatol       Date:  1989-06       Impact factor: 1.588

6.  A comparison of the new topical antibiotic mupirocin ('Bactroban') with oral antibiotics in the treatment of skin infections in general practice.

Authors:  J W Villiger; W D Robertson; K Kanji; M Ah Chan; J Fetherston; I K Hague; D Haycock; P Hunter
Journal:  Curr Med Res Opin       Date:  1986       Impact factor: 2.580

7.  Double-blind study comparing erythromycin and mupirocin for treatment of impetigo in children: implications of a high prevalence of erythromycin-resistant Staphylococcus aureus strains.

Authors:  R Dagan; Y Bar-David
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

8.  Cost-effectiveness of erythromycin versus mupirocin for the treatment of impetigo in children.

Authors:  T D Rice; A K Duggan; C DeAngelis
Journal:  Pediatrics       Date:  1992-02       Impact factor: 7.124

9.  Randomized clinical trial of topical mupirocin versus oral erythromycin for impetigo.

Authors:  J Goldfarb; D Crenshaw; J O'Horo; E Lemon; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.